Yet another abiraterone acetate Phase II update

Data from yet another Phase II clinical trial appears to support earlier reports of the potential of abiraterone (also known as CB7630) in the management of castration-resistant prostate cancer (CRPC).

In a press release earlier today, Cougar Biotechnology has annnounced preliminary data from an ongoing study in 12 patients at the University of California San Francisco. The data were presented today at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” in Geneva, Switzerland. In this study, abiraterone, in combination with prednisone, is being administered once daily to chemotherapy-naïve, ketoconazole-naïve patients with CRPC who had progressive disease despite treatment with LHRH analogs and other hormonal therapies.

Of these 12 patients, 11 (92 percent) experienced a confirmed decline in PSA levels of > 30 percent; 9 patients (75 percent) experienced a PSA decline of > 50 percent; and 6 patients (50 percent) experienced PSA declines of > 90 percent. In addition, 2 (17 percent) of the 12 patients experienced undetectable PSA levels (<0.1 ng/ml) after treatment with abiraterone. Of the 12 evaluable patients, 10 (83 percent) continue to be treated after at least 6 months.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: